Holen Sie sich die Stockscreener-App
8.70
1.16%
0.10
Handel nachbörslich:
8.70
Bicycle Therapeutics Plc Adr Aktie (BCYC) Neueste Nachrichten
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World
Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World
Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World
Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
William Blair Brokers Decrease Earnings Estimates for TLX - Defense World
Principal Financial Group Inc. Boosts Stake in Capri Holdings Limited (NYSE:CPRI) - Defense World
First Northwest Bancorp (FNWB) Expected to Announce Quarterly Earnings on Thursday - Defense World
The Bank of Nova Scotia (TSE:BNS) Receives Average Rating of “Hold” from Analysts - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up – Should You Buy? - Defense World
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com India
Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 7.40 - DWinneX
Bicycle Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com South Africa
How should investors view Bicycle Therapeutics Plc ADR (BCYC)? - uspostnews.com
PBF Energy Inc [PBF] Records 50-Day SMA of $19.79 - knoxdaily.com
UGI Corp [UGI] Records 200-Day SMA of $27.63 - knoxdaily.com
Cellebrite DI Ltd [NASDAQ: CLBT] Sees Increase in Stock Value - knoxdaily.com
Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.69 % on Wednesday - knoxdaily.com
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading - MSN
Bicycle Therapeutics Plc ADR Inc. (BCYC) Price Performance: The Role of Supply and Demand - investchronicle.com
Fastenal Co (FAST) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 By Investing.com - Investing.com South Africa
Bicycle therapeutics COO Alistair Milnes sells $16,850 in stock By Investing.com - Investing.com South Africa
Bicycle Therapeutics chief product officer sells shares worth $5,735 - Investing.com
Bicycle Therapeutics CEO Lee Kevin sells shares worth $43,612 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock - Investing.com
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 By Investing.com - Investing.com UK
Bicycle Therapeutics stock hits 52-week low at $8.6 amid downturn By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India
Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa
Bicycle Therapeutics’ SWOT analysis: innovative platform drives stock potential - Investing.com India
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Jefferies cuts Bicycle Therapeutics price target to $42 from $53 By Investing.com - Investing.com South Africa
Bicycle Therapeutics stock holds $33 target, Buy rating at Rodman By Investing.com - Investing.com South Africa
Mizuho maintains Harmony Biosciences $42 target, Outperform rating - Investing.com India
Mizuho maintains Harmony Biosciences $42 target, Outperform rating By Investing.com - Investing.com South Africa
Bicycle Therapeutics' SWOT analysis: platform potential drives stock outlook - Investing.com India
Bicycle Therapeutics reports promising cancer drug trial results - Investing.com
Bicycle Therapeutics exec sells $30k in shares - Investing.com
Bicycle Therapeutics spotlights cancer treatment targets - Investing.com
Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Oppenheimer backs Bicycle Therapeutics' BRC platform, reiterates $48 stock PT - Investing.com UK
Bicycle therapeutics CEO sells shares worth over $71k - Investing.com
Europe Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research
South Korea Peptide Drug Conjugates Market Size & Outlook, 2030 - Grand View Research
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio - Nasdaq
Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert (NASDAQ:BCYC) - Seeking Alpha
Is Bicycle Therapeutics (BCYC) Outperforming Other Medical Stocks This Year? - Yahoo Finance
BCYC Stock Quote Price and Forecast - CNN
Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates - Nasdaq
B. Riley Securities Upgrades Bicycle Therapeutics PlcADR (BCYC) - Nasdaq
Cantor Fitzgerald Reiterates Bicycle Therapeutics PlcADR (BCYC) Overweight Recommendation - Nasdaq
Oppenheimer Reiterates Bicycle Therapeutics PlcADR (BCYC) Outperform Recommendation - Nasdaq
Wall Street Analysts Think Bicycle Therapeutics PLC Sponsored ADR (BCYC) Could Surge 146.31%: Read This Before Placing a Bet - Nasdaq
JMP Securities Reiterates Bicycle Therapeutics PlcADR (BCYC) Market Outperform Recommendation - Nasdaq
Bicycle Therapeutics PlcADR Shares Close the Day 24.5% HigherDaily Wrap - Nasdaq
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs - Nasdaq
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod - Benzinga
Bicycle Therapeutics (BCYC) Stock Price, News & Analysis - MarketBeat
Bicycle TherapeuticsBCYCStock Price Today - Zacks Investment Research
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):